Related Experiment Video
Updated: Mar 19, 2026
Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
Abstract:
Preliminary findings from MyPathway, an ongoing phase II basket trial, indicate that matching molecular abnormalities of patients' tumors to relevant targeted therapies-albeit outside a given drug's FDA-approved indication-is both feasible and promising. Notably, patients with HER2-amplified colorectal, bladder, and biliary cancers responded well to the combination of trastuzumab and pertuzumab.
Insights
Matching tumor molecular abnormalities to targeted therapies is feasible and promising. Patients with HER2-amplified cancers showed positive responses to trastuzumab and pertuzumab.
Area of Science:
- Oncology
- Molecular Biology
- Clinical Trials
Background:
- The MyPathway trial is a phase II basket study investigating targeted therapies.
- The study focuses on matching molecular abnormalities in tumors to specific treatments.
- Treatments are explored outside of their FDA-approved indications.
Discussion:
- Preliminary results suggest feasibility and promise in this personalized medicine approach.
- The strategy involves identifying and targeting specific genetic mutations within tumors.
- This contrasts with traditional one-size-fits-all treatment protocols.
Key Insights:
- Patients with HER2-amplified colorectal, bladder, and biliary cancers demonstrated significant response.
- The combination therapy of trastuzumab and pertuzumab was notably effective in these cases.
- This highlights the potential of molecularly guided therapy in rare or difficult-to-treat cancers.
Outlook:
- Further research is warranted to validate these findings in larger patient cohorts.
- This approach could expand treatment options for various cancer types.
- The study paves the way for more precise and effective cancer therapies.
